Vitasora Health (VHL) Status update summary

Revenue growth and operational performance

• Per patient per month revenue is up 15% year-on-year, and daily billing rates have increased by 35% due to improved productivity and reimbursement rates.

• Dual enrollment in Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) has doubled to 9%, with a target of 50% dual enrollment by year-end, and a new patient pool of ~40,000 from existing clients is expected to generate $360,000–$720,000 in additional monthly revenue.

• Patient engagement has risen by 10%, now reaching two-thirds of enrolled patients.

• Cash flow breakeven is targeted within the next three to six months, driven by fee-for-service business and operational improvements.

• Immediate revenue growth is driven by US expansion, fee-for-service business, stacked revenue, and new patient volume expansion.

Regulatory and reimbursement tailwinds

• CMS increased reimbursement rates for CCM by 8% starting January 1, and RPM reimbursement rates have also increased, supporting ongoing revenue growth.

• RPM qualification requirements reduced from 16 to 2 days of data, boosting conversion rates from 50–60% to 90%.

• Medicare and the AMA strongly support CCM and RPM, ensuring their continued availability and growth.

• Compounding revenue growth is expected from policy tailwinds, dual enrollment, and platform leverage.

Technology and automation initiatives

• Launching a proprietary EMR system with embedded AI on April 1 to streamline patient eligibility, data access, and coding.

• AI will cross-reference clinical and prescription data, increasing the yield of eligible patients for reimbursement.

• Direct EMR integration eliminates manual data transfer, improving efficiency and staff utilization.

• Automation and operational investments accelerate billing cycles, increase eligible patient capture, and improve reimbursement consistency.

• Direct EMR data transfer and AI-driven eligibility improve patient analysis, selection, and billing consistency.